Ascendis Pharma

Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist
Fierce Biotech
Mon, 11/4/24 - 11:13 am
Novo Nordisk
Ascendis Pharma
biobucks
drug development
Ascendis trial data piles pressure on BioMarin
BioPharma Dive
Wed, 09/18/24 - 01:42 pm
Ascendis Pharma
Biomarin
Voxzogo
achondroplasia
MBX files for IPO, seeking cash to take challenger to Ascendis' Yorvipath into phase 3
Fierce Biotech
Mon, 08/26/24 - 10:09 am
MBX Biosciences
IPOs
Ascendis Pharma
Yorvipath
A First for Hypoparathyroidism — Yorvipath (Palopegteriparatide) Earns FDA Nod
Xtalks
Thu, 08/22/24 - 09:51 pm
Yorvipath
FDA
hypoparathyroidism
Ascendis Pharma
Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath
Fierce Pharma
Mon, 08/12/24 - 11:35 am
Ascendis Pharma
hypoparathyroidism
FDA
Yorvipath
Another delay for Ascendis' hormone therapy as FDA extends review by 3 months
Fierce Pharma
Tue, 05/14/24 - 11:06 pm
Ascendis Pharma
Transcon PTH
FDA
hypoparathyroidism
Unpartnered assets: on the shelf or hidden treasure?
EP Vantage
Thu, 06/15/23 - 09:54 am
R&D
ALX Oncology
Argenx
Ascendis Pharma
Cytokinetics
Karuna Therapeutics
Madrigal Pharmaceuticals
Protagonist Therapeutics
Prothena
Ultragenyx Pharmaceutical
Unique Pharma
Ventyx Biosciences
FDA cites ‘deficiencies’ in Ascendis’ application for parathyroid drug, jeopardizing potential approval
Endpoints
Tue, 04/4/23 - 12:32 pm
Ascendis Pharma
hypoparathyroidism
FDA
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge
Investors Business Daily
Thu, 05/12/22 - 10:18 am
Ascendis Pharma
Skytrofa
earnings
Pfizer stumbles close to finish line in growth hormone race, extending the lead of rival Ascendis
Fierce Biotech
Mon, 09/27/21 - 10:51 am
Pfizer
growth hormone deficiency
FDA
Ascendis Pharma
Ascendis crosses FDA finish line with once-weekly growth hormone—but Pfizer is hot on its trail
Fierce Pharma
Wed, 08/25/21 - 09:29 pm
Ascendis Pharma
Skytrofa
growth hormone deficiency
FDA
The big approvals still on the cards for 2021
EP Vantage
Thu, 06/17/21 - 11:00 am
FDA
drug approvals
Argenx
Novartis
AstraZeneca
Astellas
UCB Pharma
Ascendis Pharma
ChemoCentryx
Axsome Therapeutics
Go or no go? Aducanumab’s day of reckoning
EP Vantage
Thu, 05/27/21 - 10:56 am
Biogen
FDA
aducanumab
Ascendis Pharma
Novo Nordisk
TransCon hGH
semaglutide
Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
The window of opportunity opens wider for Ascendis
EP Vantage
Tue, 09/29/20 - 11:53 am
Ascendis Pharma
Transcon PTH
hypoparathyroidism
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sun, 06/23/19 - 02:04 pm
Merck
Keytruda
Melinta Therapeutics
Amag Pharmaceuticals
Palatin
Acer Therapeutics
Sanofi
Regeneron
Alexion
Pfizer
Roche
Navidea Biopharmaceuticals
Ascendis Pharma
Scholar Rock
Adaptive Biotechnologies
BridgeBio
IPOs
G Medical Innovations
Karuna
Morphic Therapeutics